Global Biotechnology Contract Manufacturing Market Size Study & Forecast, by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), and Type and Regional Forecasts 2025-2035

Description

The Global Biotechnology Contract Manufacturing Market is valued at approximately USD 40.1 billion in 2024 and is projected to expand at a robust CAGR of 11.10% over the forecast period 2025-2035. Biotechnology contract manufacturing involves outsourcing the production of biologics and biosimilars to specialized service providers who possess advanced capabilities in process development, scale-up, and commercial manufacturing. This model enables pharmaceutical and biotech companies to optimize operational efficiencies, reduce capital expenditure, and accelerate time-to-market for complex biologics. The market growth is driven by an increasing pipeline of biologic drugs, rising adoption of biosimilars, and the growing trend of outsourcing manufacturing activities to leverage expertise, infrastructure, and regulatory compliance capabilities of contract manufacturing organizations (CMOs).

The demand for biotechnology contract manufacturing has surged due to the escalating complexity of biologics and biosimilars production, requiring sophisticated equipment, stringent quality control, and specialized technical expertise. According to industry reports, the global biologics market witnessed significant expansion in 2023 and 2024, which in turn has stimulated the need for high-capacity contract manufacturing solutions. Moreover, strategic partnerships, mergers, and collaborations between pharmaceutical firms and CMOs are fostering innovation, enhancing production capacity, and broadening market reach. However, regulatory scrutiny and the high cost of biologics manufacturing may impose challenges for smaller players, potentially tempering growth during the forecast period of 2025-2035.

The detailed segments and sub-segments included in the report are:

By Source:

Human-derived
Animal-derived
Microbial
Plant-based

By Service (Process Development):

Cell Line Development
Upstream Processing
Downstream Processing
Analytical Services

By Drug Type:

Biologics
Biosimilars

By Type:

Contract Manufacturing
Contract Development and Manufacturing

By Region:

North America

U.S.
Canada

Europe

UK
Germany
France
Spain
Italy
ROE

Asia Pacific

China
India
Japan
Australia
South Korea
RoAPAC

Latin America

Brazil
Mexico

Middle East & Africa

UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Biologics Segment is Expected to Dominate the Market

Among the drug type segments, biologics are anticipated to dominate the biotechnology contract manufacturing market, holding the largest share throughout the forecast period. The dominance is primarily driven by the rapid development and commercialization of monoclonal antibodies, recombinant proteins, and other advanced therapeutics that necessitate high-capacity contract manufacturing solutions. Biosimilars, however, are emerging as a fast-growing segment due to cost-effectiveness, patent expirations of original biologics, and increasing adoption in both developed and emerging markets. While biologics maintain a commanding presence in terms of market share, biosimilars represent significant growth potential fueled by increasing healthcare affordability and regulatory approvals.

Contract Development and Manufacturing Leads in Revenue Contribution

From a service perspective, contract development and manufacturing (CDMO) dominates revenue generation owing to its comprehensive offerings, including process development, scale-up, and commercial production capabilities. This segment is critical for companies aiming to reduce operational burden and accelerate biologic production without investing in large-scale manufacturing facilities. On the other hand, pure contract manufacturing services continue to contribute steadily due to ongoing demand for large-volume production of well-established biologics. This dual-market dynamic reflects both the revenue-generating dominance of CDMOs and the consistent adoption of traditional contract manufacturing models, driven by operational efficiency and regulatory compliance considerations.

North America continues to hold a leading position in the biotechnology contract manufacturing market, owing to the presence of well-established CMOs, advanced infrastructure, and a strong pipeline of biologic therapeutics. Europe follows closely, supported by robust regulatory frameworks, significant R&D investments, and active collaborations between biotech firms and manufacturing partners. Meanwhile, Asia Pacific is projected to be the fastest-growing region during the forecast period, fueled by rising biologics production, government incentives, increasing healthcare infrastructure, and cost advantages in countries such as China and India. Latin America and the Middle East & Africa are gradually expanding their biotechnology contract manufacturing capabilities, driven by strategic partnerships and growing demand for biologics and biosimilars.

Major market players included in this report are:

Lonza Group AG
Samsung Biologics
WuXi AppTec
Catalent, Inc.
Boehringer Ingelheim GmbH
Fujifilm Diosynth Biotechnologies
Patheon N.V.
Recipharm AB
Baxter International Inc.
Cobra Biologics
Ajinomoto Bio-Pharma Services
Piramal Pharma Solutions
Sandoz International GmbH
Rentschler Biopharma SE
Novasep

Global Biotechnology Contract Manufacturing Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained above.

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Biotechnology Contract Manufacturing Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Biotechnology Contract Manufacturing Market Forces Analysis

3.1. Market Forces Shaping The Global Biotechnology Contract Manufacturing Market (2024-2035)
3.2. Drivers
- 3.2.1. increasing pipeline of biologic drugs
- 3.2.2. rising adoption of biosimilars
3.3. Restraints
- 3.3.1. high cost of biologics manufacturing
3.4. Opportunities
- 3.4.1. growing trend of outsourcing manufacturing

Chapter 4. Global Biotechnology Contract Manufacturing Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Biotechnology Contract Manufacturing Market Size & Forecasts by Source 2025-2035

5.1. Market Overview
5.2. Global Biotechnology Contract Manufacturing Market Performance - Potential Analysis (2025)
5.3. Human-derived
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Animal-derived
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. Microbial
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. Plant-based
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Biotechnology Contract Manufacturing Market Size & Forecasts by Service (Process Development) 2025-2035

6.1. Market Overview
6.2. Global Biotechnology Contract Manufacturing Market Performance - Potential Analysis (2025)
6.3. Cell Line Development
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Upstream Processing
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Downstream Processing
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Analytical Services
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Biotechnology Contract Manufacturing Market Size & Forecasts by Drug type 2025-2035

7.1. Market Overview
7.2. Global Biotechnology Contract Manufacturing Market Performance - Potential Analysis (2025)
7.3. Biologics
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
7.4. Biosimilars
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Biotechnology Contract Manufacturing Market Size & Forecasts by type 2025-2035

8.1. Market Overview
8.2. Global Biotechnology Contract Manufacturing Market Performance - Potential Analysis (2025)
8.3. Contract Manufacturing
- 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.3.2. Market size analysis, by region, 2025-2035
8.4. Contract Development and Manufacturing
- 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.4.2. Market size analysis, by region, 2025-2035

Chapter 9. Global Biotechnology Contract Manufacturing Market Size & Forecasts by Region 2025-2035

9.1. Growth Biotechnology Contract Manufacturing Market, Regional Market Snapshot
9.2. Top Leading & Emerging Countries
9.3. North America Biotechnology Contract Manufacturing Market
- 9.3.1. U.S. Biotechnology Contract Manufacturing Market
  - 9.3.1.1. Source breakdown size & forecasts, 2025-2035
  - 9.3.1.2. Service breakdown size & forecasts, 2025-2035
  - 9.3.1.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.3.1.4. Type breakdown size & forecasts, 2025-2035
- 9.3.2. Canada Biotechnology Contract Manufacturing Market
  - 9.3.2.1. Source breakdown size & forecasts, 2025-2035
  - 9.3.2.2. Service breakdown size & forecasts, 2025-2035
  - 9.3.2.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.3.2.4. Type breakdown size & forecasts, 2025-2035
9.4. Europe Biotechnology Contract Manufacturing Market
- 9.4.1. UK Biotechnology Contract Manufacturing Market
  - 9.4.1.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.1.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.1.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.1.4. Type breakdown size & forecasts, 2025-2035
- 9.4.2. Germany Biotechnology Contract Manufacturing Market
  - 9.4.2.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.2.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.2.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.2.4. Type breakdown size & forecasts, 2025-2035
- 9.4.3. France Biotechnology Contract Manufacturing Market
  - 9.4.3.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.3.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.3.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.3.4. Type breakdown size & forecasts, 2025-2035
- 9.4.4. Spain Biotechnology Contract Manufacturing Market
  - 9.4.4.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.4.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.4.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.4.4. Type breakdown size & forecasts, 2025-2035
- 9.4.5. Italy Biotechnology Contract Manufacturing Market
  - 9.4.5.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.5.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.5.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.5.4. Type breakdown size & forecasts, 2025-2035
- 9.4.6. Rest of Europe Biotechnology Contract Manufacturing Market
  - 9.4.6.1. Source breakdown size & forecasts, 2025-2035
  - 9.4.6.2. Service breakdown size & forecasts, 2025-2035
  - 9.4.6.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.4.6.4. Type breakdown size & forecasts, 2025-2035
9.5. Asia Pacific Biotechnology Contract Manufacturing Market
- 9.5.1. China Biotechnology Contract Manufacturing Market
  - 9.5.1.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.1.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.1.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.1.4. Type breakdown size & forecasts, 2025-2035
- 9.5.2. India Biotechnology Contract Manufacturing Market
  - 9.5.2.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.2.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.2.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.2.4. Type breakdown size & forecasts, 2025-2035
- 9.5.3. Japan Biotechnology Contract Manufacturing Market
  - 9.5.3.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.3.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.3.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.3.4. Type breakdown size & forecasts, 2025-2035
- 9.5.4. Australia Biotechnology Contract Manufacturing Market
  - 9.5.4.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.4.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.4.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.4.4. Type breakdown size & forecasts, 2025-2035
- 9.5.5. South Korea Biotechnology Contract Manufacturing Market
  - 9.5.5.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.5.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.5.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.5.4. Type breakdown size & forecasts, 2025-2035
- 9.5.6. Rest of APAC Biotechnology Contract Manufacturing Market
  - 9.5.6.1. Source breakdown size & forecasts, 2025-2035
  - 9.5.6.2. Service breakdown size & forecasts, 2025-2035
  - 9.5.6.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.5.6.4. Type breakdown size & forecasts, 2025-2035
9.6. Latin America Biotechnology Contract Manufacturing Market
- 9.6.1. Brazil Biotechnology Contract Manufacturing Market
  - 9.6.1.1. Source breakdown size & forecasts, 2025-2035
  - 9.6.1.2. Service breakdown size & forecasts, 2025-2035
  - 9.6.1.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.6.1.4. Type breakdown size & forecasts, 2025-2035
- 9.6.2. Mexico Biotechnology Contract Manufacturing Market
  - 9.6.2.1. Source breakdown size & forecasts, 2025-2035
  - 9.6.2.2. Service breakdown size & forecasts, 2025-2035
  - 9.6.2.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.6.2.4. Type breakdown size & forecasts, 2025-2035
9.7. Middle East and Africa Biotechnology Contract Manufacturing Market
- 9.7.1. UAE Biotechnology Contract Manufacturing Market
  - 9.7.1.1. Source breakdown size & forecasts, 2025-2035
  - 9.7.1.2. Service breakdown size & forecasts, 2025-2035
  - 9.7.1.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.7.1.4. Type breakdown size & forecasts, 2025-2035
- 9.7.2. Saudi Arabia (KSA) Biotechnology Contract Manufacturing Market
  - 9.7.2.1. Source breakdown size & forecasts, 2025-2035
  - 9.7.2.2. Service breakdown size & forecasts, 2025-2035
  - 9.7.2.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.7.2.4. Type breakdown size & forecasts, 2025-2035
- 9.7.3. South Africa Biotechnology Contract Manufacturing Market
  - 9.7.3.1. Source breakdown size & forecasts, 2025-2035
  - 9.7.3.2. Service breakdown size & forecasts, 2025-2035
  - 9.7.3.3. Drug type breakdown size & forecasts, 2025-2035
  - 9.7.3.4. Type breakdown size & forecasts, 2025-2035

Chapter 10. Competitive Intelligence

10.1. Top Market Strategies
10.2. Lonza Group AG
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Financial Performance (Subject to Data Availability)
- 10.2.5. Product/Services Port
- 10.2.6. Recent Development
- 10.2.7. Market Strategies
- 10.2.8. SWOT Analysis
10.3. Samsung Biologics
10.4. WuXi AppTec
10.5. Catalent, Inc.
10.6. Boehringer Ingelheim GmbH
10.7. Fujifilm Diosynth Biotechnologies
10.8. Patheon N.V.
10.9. Recipharm AB
10.10. Baxter International Inc.
10.11. Cobra Biologics
10.12. Ajinomoto Bio-Pharma Services
10.13. Piramal Pharma Solutions
10.14. Sandoz International GmbH
10.15. Rentschler Biopharma SE
10.16. Novasep